Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.

Mitochondrial aldehyde dehydrogenase-2 (ALDH-2) is involved in preconditioning pathways, but its role in remote ischaemic preconditioning (rIPC) is unknown. We investigated its role in animal and human models of rIPC. (i) In a rabbit model of myocardial infarction, rIPC alone reduced infarct size [6...

Ամբողջական նկարագրություն

Մատենագիտական մանրամասներ
Հիմնական հեղինակներ: Contractor, H, Støttrup, N, Cunnington, C, Manlhiot, C, Diesch, J, Ormerod, J, Jensen, R, Bøtker, H, Redington, A, Schmidt, MR, Ashrafian, H, Kharbanda, R
Ձևաչափ: Journal article
Լեզու:English
Հրապարակվել է: 2013
_version_ 1826270158712209408
author Contractor, H
Støttrup, N
Cunnington, C
Manlhiot, C
Diesch, J
Ormerod, J
Jensen, R
Bøtker, H
Redington, A
Schmidt, MR
Ashrafian, H
Kharbanda, R
author_facet Contractor, H
Støttrup, N
Cunnington, C
Manlhiot, C
Diesch, J
Ormerod, J
Jensen, R
Bøtker, H
Redington, A
Schmidt, MR
Ashrafian, H
Kharbanda, R
author_sort Contractor, H
collection OXFORD
description Mitochondrial aldehyde dehydrogenase-2 (ALDH-2) is involved in preconditioning pathways, but its role in remote ischaemic preconditioning (rIPC) is unknown. We investigated its role in animal and human models of rIPC. (i) In a rabbit model of myocardial infarction, rIPC alone reduced infarct size [69 ± 5.8 % (n = 11) to 40 ± 6.5 % (n = 12), P = 0.019]. However, rIPC protection was lost after pre-treatment with the ALDH-2 inhibitor cyanamide (62 ± 7.6 % controls, n = 10, versus 61 ± 6.9 % rIPC after cyanamide, n = 10, P > 0.05). (ii) In a forearm plethysmography model of endothelial ischaemia-reperfusion injury, 24 individuals of Asian ethnic origin underwent combined rIPC and ischaemia-reperfusion (IR). 11 had wild-type (WT) enzyme and 13 carried the Glu504Lys (ALDH2*2) polymorphism (rendering ALDH-2 functionally inactive). In WT individuals, rIPC protected against impairment of response to acetylcholine (P = 0.9), but rIPC failed to protect carriers of Glu504Lys polymorphism (P = 0.004). (iii) In a second model of endothelial IR injury, 12 individuals participated in a double-blind placebo-controlled crossover study, receiving the ALDH-2 inhibitor disulfiram 600 mg od or placebo for 48 h prior to assessment of flow-mediated dilation (FMD) before and after combined rIPC and IR. With placebo, rIPC was effective with no difference in FMD before and after IR (6.18 ± 1.03 % and 4.76 ± 0.93 % P = 0.1), but disulfiram inhibited rIPC with a reduction in FMD after IR (7.87 ± 1.27 % and 3.05 ± 0.53 %, P = 0.001). This study demonstrates that ALDH-2 is involved in the rIPC pathway in three distinct rabbit and human models. This has potential implications for future clinical studies of remote conditioning.
first_indexed 2024-03-06T21:36:27Z
format Journal article
id oxford-uuid:466f496e-f345-4db8-a842-33bb5c2b1567
institution University of Oxford
language English
last_indexed 2024-03-06T21:36:27Z
publishDate 2013
record_format dspace
spelling oxford-uuid:466f496e-f345-4db8-a842-33bb5c2b15672022-03-26T15:13:38ZAldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:466f496e-f345-4db8-a842-33bb5c2b1567EnglishSymplectic Elements at Oxford2013Contractor, HStøttrup, NCunnington, CManlhiot, CDiesch, JOrmerod, JJensen, RBøtker, HRedington, ASchmidt, MRAshrafian, HKharbanda, RMitochondrial aldehyde dehydrogenase-2 (ALDH-2) is involved in preconditioning pathways, but its role in remote ischaemic preconditioning (rIPC) is unknown. We investigated its role in animal and human models of rIPC. (i) In a rabbit model of myocardial infarction, rIPC alone reduced infarct size [69 ± 5.8 % (n = 11) to 40 ± 6.5 % (n = 12), P = 0.019]. However, rIPC protection was lost after pre-treatment with the ALDH-2 inhibitor cyanamide (62 ± 7.6 % controls, n = 10, versus 61 ± 6.9 % rIPC after cyanamide, n = 10, P > 0.05). (ii) In a forearm plethysmography model of endothelial ischaemia-reperfusion injury, 24 individuals of Asian ethnic origin underwent combined rIPC and ischaemia-reperfusion (IR). 11 had wild-type (WT) enzyme and 13 carried the Glu504Lys (ALDH2*2) polymorphism (rendering ALDH-2 functionally inactive). In WT individuals, rIPC protected against impairment of response to acetylcholine (P = 0.9), but rIPC failed to protect carriers of Glu504Lys polymorphism (P = 0.004). (iii) In a second model of endothelial IR injury, 12 individuals participated in a double-blind placebo-controlled crossover study, receiving the ALDH-2 inhibitor disulfiram 600 mg od or placebo for 48 h prior to assessment of flow-mediated dilation (FMD) before and after combined rIPC and IR. With placebo, rIPC was effective with no difference in FMD before and after IR (6.18 ± 1.03 % and 4.76 ± 0.93 % P = 0.1), but disulfiram inhibited rIPC with a reduction in FMD after IR (7.87 ± 1.27 % and 3.05 ± 0.53 %, P = 0.001). This study demonstrates that ALDH-2 is involved in the rIPC pathway in three distinct rabbit and human models. This has potential implications for future clinical studies of remote conditioning.
spellingShingle Contractor, H
Støttrup, N
Cunnington, C
Manlhiot, C
Diesch, J
Ormerod, J
Jensen, R
Bøtker, H
Redington, A
Schmidt, MR
Ashrafian, H
Kharbanda, R
Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.
title Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.
title_full Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.
title_fullStr Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.
title_full_unstemmed Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.
title_short Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models.
title_sort aldehyde dehydrogenase 2 inhibition blocks remote preconditioning in experimental and human models
work_keys_str_mv AT contractorh aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT støttrupn aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT cunningtonc aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT manlhiotc aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT dieschj aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT ormerodj aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT jensenr aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT bøtkerh aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT redingtona aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT schmidtmr aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT ashrafianh aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels
AT kharbandar aldehydedehydrogenase2inhibitionblocksremotepreconditioninginexperimentalandhumanmodels